-
公开(公告)号：US20050004114A1
公开(公告)日：2005-01-06
申请号：US10835818
申请日：2004-04-30
申请人： Darren Whitehouse , Shaojing Hu , Haiquan Fang , Kerry Combs , Michael Van Zandt
发明人： Darren Whitehouse , Shaojing Hu , Haiquan Fang , Kerry Combs , Michael Van Zandt
IPC分类号： A61P3/10 , C07D401/14 , C07D405/10 , C07D405/12 , C07D405/14 , C07D409/10 , C07D417/10 , C07D417/12 , C07D417/02 , A61K31/195 , C07D413/02 , C07
CPC分类号： C07D401/14 , C07D405/10 , C07D405/12 , C07D405/14 , C07D409/10 , C07D417/10 , C07D417/12
摘要： The present invention relates to compounds and pharmaceutically acceptable salts of formula (I): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.
摘要翻译： 本发明涉及式（I）的化合物和药学上可接受的盐：其可用于治疗与胰岛素抵抗，瘦素抵抗或高血糖相关的代谢紊乱。 本发明的化合物包括可用于治疗糖尿病和其它PTP介导的疾病如癌症，神经变性疾病等的蛋白质酪氨酸磷酸酶抑制剂，特别是蛋白质酪氨酸磷酸酶-1B（PTP-1B）。 还公开了包含本发明化合物的药物组合物和使用这些化合物治疗上述病症的方法。
-
公开(公告)号：US20060100251A1
公开(公告)日：2006-05-11
申请号：US11262423
申请日：2005-10-28
IPC分类号： A61K31/44 , A61K31/195 , C07D213/55 , C07C311/42
CPC分类号： C07C311/21 , C07C69/65 , C07C311/29 , C07D213/55
摘要： The present invention relates to compounds and pharmaceutically acceptable salts of formula I: which are useful in the treatment of metabolic disorders related to insulin resistance or hyperglycemia. These compounds include inhibitors of protein tyrosine phosphatase (PTP-1B) that are useful in the treatment of diabetes and other PTP-1B mediated diseases, such as cancer, neurodegenerative diseases and the like. The compounds of the invention are also useful in pharmaceutical compositions and methods of treating the aforementioned conditions.
摘要翻译： 本发明涉及式I化合物和药学上可接受的盐：其可用于治疗与胰岛素抵抗或高血糖相关的代谢紊乱。 这些化合物包括可用于治疗糖尿病和其它PTP-1B介导的疾病如癌症，神经变性疾病等的蛋白质酪氨酸磷酸酶（PTP-1B）的抑制剂。 本发明的化合物也可用于治疗上述病症的药物组合物和方法。
-
公开(公告)号：US20060122257A1
公开(公告)日：2006-06-08
申请号：US11283437
申请日：2005-11-18
IPC分类号： A61K31/381 , A61K31/343 , A61K31/198 , C07C235/32 , C07D333/76
CPC分类号： C07D307/79 , C07C271/22 , C07C311/29 , C07C317/14 , C07C317/32 , C07C323/52 , C07C323/65 , C07C2603/74 , C07D307/91
摘要： Disclosed are compounds and pharmaceutically acceptable salts of formula (A): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.
-
公开(公告)号：US20050004369A1
公开(公告)日：2005-01-06
申请号：US10835924
申请日：2004-04-30
IPC分类号： C07C311/19 , C07C311/29 , C07D209/08 , C07D233/62 , C07D277/38 , C07D307/79 , C07D307/80 , C07D307/81 , C07D307/91 , C07D401/04 , C07D263/02
CPC分类号： C07D307/79 , C07C311/19 , C07C311/29 , C07D209/08 , C07D307/80 , C07D307/81 , C07D307/91 , C07D401/04
摘要： Disclosed are compounds and pharmaceutically acceptable salts of formula (A): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.
摘要翻译： 公开了式（A）的化合物和药学上可接受的盐：其可用于治疗与胰岛素抵抗，瘦素抗性或高血糖相关的代谢紊乱。 本发明的化合物包括可用于治疗糖尿病和其它PTP介导的疾病如癌症，神经变性疾病等的蛋白质酪氨酸磷酸酶抑制剂，特别是蛋白质酪氨酸磷酸酶-1B（PTP-1B）。 还公开了包含本发明化合物的药物组合物和使用这些化合物治疗上述病症的方法。
-
公开(公告)号：US07329680B2
公开(公告)日：2008-02-12
申请号：US10835818
申请日：2004-04-30
IPC分类号： C07D277/38 , A61K31/425
CPC分类号： C07D401/14 , C07D405/10 , C07D405/12 , C07D405/14 , C07D409/10 , C07D417/10 , C07D417/12
摘要： The present invention relates to compounds and pharmaceutically acceptable salts of formula (I): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.
摘要翻译： 本发明涉及式（I）的化合物和药学上可接受的盐：其可用于治疗与胰岛素抵抗，瘦素抵抗或高血糖相关的代谢紊乱。 本发明的化合物包括可用于治疗糖尿病和其它PTP介导的疾病如癌症，神经变性疾病等的蛋白质酪氨酸磷酸酶抑制剂，特别是蛋白质酪氨酸磷酸酶-1B（PTP-1B）。 还公开了包含本发明化合物的药物组合物和使用这些化合物治疗上述病症的方法。
-
公开(公告)号：US20080146574A1
公开(公告)日：2008-06-19
申请号：US12029708
申请日：2008-02-12
IPC分类号： A61K31/53 , A61K31/497 , C07D403/14 , C07D405/10 , C07D239/24 , A61P3/10
CPC分类号： C07D401/14 , C07D405/10 , C07D405/12 , C07D405/14 , C07D409/10 , C07D417/10 , C07D417/12
摘要： The present invention relates to compounds and pharmaceutically acceptable salts of formula (I): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia.Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.
摘要翻译： 本发明涉及式（I）的化合物和药学上可接受的盐：其可用于治疗与胰岛素抵抗，瘦素抵抗或高血糖相关的代谢紊乱。 本发明的化合物包括可用于治疗糖尿病和其它PTP介导的疾病如癌症，神经变性疾病等的蛋白质酪氨酸磷酸酶抑制剂，特别是蛋白质酪氨酸磷酸酶-1B（PTP-1B）。 还公开了包含本发明化合物的药物组合物和使用这些化合物治疗上述病症的方法。
-
公开(公告)号：US07465825B2
公开(公告)日：2008-12-16
申请号：US11283437
申请日：2005-11-18
IPC分类号： C07C229/00 , C07D333/00 , C07D307/91 , A01N43/12 , A01N43/08
CPC分类号： C07D307/79 , C07C271/22 , C07C311/29 , C07C317/14 , C07C317/32 , C07C323/52 , C07C323/65 , C07C2603/74 , C07D307/91
摘要： Disclosed are compounds and pharmaceutically acceptable salts of formula (A): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.
摘要翻译： 公开了式（A）的化合物和药学上可接受的盐：其可用于治疗与胰岛素抵抗，瘦素抗性或高血糖相关的代谢紊乱。 本发明的化合物包括可用于治疗糖尿病和其它PTP介导的疾病如癌症，神经变性疾病等的蛋白质酪氨酸磷酸酶抑制剂，特别是蛋白质酪氨酸磷酸酶-1B（PTP-1B）。 还公开了包含本发明化合物的药物组合物和使用这些化合物治疗上述病症的方法。
-
公开(公告)号：US07524878B2
公开(公告)日：2009-04-28
申请号：US10835924
申请日：2004-04-30
IPC分类号： A61K31/341 , A61K31/404 , C07D209/04 , C07D307/79
CPC分类号： C07D307/79 , C07C311/19 , C07C311/29 , C07D209/08 , C07D307/80 , C07D307/81 , C07D307/91 , C07D401/04
摘要： Disclosed are compounds and pharmaceutically acceptable salts of formula (A): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.
摘要翻译： 公开了式（A）的化合物和药学上可接受的盐：其可用于治疗与胰岛素抵抗，瘦素抗性或高血糖相关的代谢紊乱。 本发明的化合物包括可用于治疗糖尿病和其它PTP介导的疾病如癌症，神经变性疾病等的蛋白质酪氨酸磷酸酶抑制剂，特别是蛋白质酪氨酸磷酸酶-1B（PTP-1B）。 还公开了包含本发明化合物的药物组合物和使用这些化合物治疗上述病症的方法。
-
![Azabicyclo[2.2.1]Heptane Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands](/abs-image/US/2011/10/27/US20110263605A1/abs.jpg.150x150.jpg)
9.发明申请Azabicyclo[2.2.1]Heptane Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands 有权氮杂双环[2.2.1]庚烷化合物作为α-7烟碱乙酰胆碱受体配体公开(公告)号：US20110263605A1
公开(公告)日：2011-10-27
申请号：US12907122
申请日：2010-10-19
申请人： Ivar M. McDonald , Robert A. Mate , James H. Cook, II , Dalton King , Richard E. Olson , Nenghui Wang , Christiana I. Iwuagwu , F. Christopher Zusi , Matthew D. Hill , Haiquan Fang , John E. Macor
发明人： Ivar M. McDonald , Robert A. Mate , James H. Cook, II , Dalton King , Richard E. Olson , Nenghui Wang , Christiana I. Iwuagwu , F. Christopher Zusi , Matthew D. Hill , Haiquan Fang , John E. Macor
IPC分类号： A61K31/439 , C07D487/00 , A61K31/506 , A61K31/497 , A61K31/53 , A61P1/00 , A61P25/28 , A61P25/18 , A61P19/02 , A61P1/04 , A61P3/10 , C07D498/20 , A61K31/519
CPC分类号： C07D498/20 , C07D519/00
摘要： The disclosure provides compounds of formula I, including Ia, Ib, Ic, or Id, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
摘要翻译： 本公开提供式I化合物，包括Ia，Ib，Ic或Id，包括其盐，以及使用该化合物的组合物和方法。 这些化合物是烟碱型α7受体的配体，可用于治疗中枢神经系统的各种疾病，特别是情感和神经退行性疾病。
-
10.发明申请Aza-Bicyclic Amine N-Oxide Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligand Pro-Drugs 有权氮杂双环胺氧化物作为α-7烟碱乙酰胆碱受体配体药物公开(公告)号：US20120108596A1
公开(公告)日：2012-05-03
申请号：US13097153
申请日：2011-04-29
申请人： Kimberley A. Lentz , Rex Denton , James H. Cook, II , Ivar M. McDonald , Dalton King , Richard E. Olson , Nenghui Wang , Robert A. Mate , Christiana I. Iwuagwu , F. Christopher Zusi , John E. Macor , Matthew D. Hill , Haiquan Fang
发明人： Kimberley A. Lentz , Rex Denton , James H. Cook, II , Ivar M. McDonald , Dalton King , Richard E. Olson , Nenghui Wang , Robert A. Mate , Christiana I. Iwuagwu , F. Christopher Zusi , John E. Macor , Matthew D. Hill , Haiquan Fang
IPC分类号： A61K31/4725 , A61P25/18 , A61P25/28 , A61K31/439 , A61K31/498 , A61K31/506 , A61K31/444 , A61K31/497 , C07D498/20 , C07D519/00
CPC分类号： C07D498/10
摘要： The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are prodrugs for ligands, agonists, and partial agonists for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
摘要翻译： 本公开内容通常涉及式I化合物，包括其盐，以及使用该化合物的组合物和方法。 这些化合物是用于烟碱型α7受体的配体，激动剂和部分激动剂的前药，并且可用于治疗中枢神经系统的各种疾病，特别是情感和神经变性疾病。
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.027 秒)
